Polycystic Kidney Disease - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 79 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Polycystic Kidney Disease - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Polycystic Kidney Disease - Pipeline Review, H1 2015', provides an overview of the Polycystic Kidney Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Polycystic Kidney Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Polycystic Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Polycystic Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Polycystic Kidney Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Polycystic Kidney Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Polycystic Kidney Disease Overview 8
Therapeutics Development 9
Pipeline Products for Polycystic Kidney Disease - Overview 9
Pipeline Products for Polycystic Kidney Disease - Comparative Analysis 10
Polycystic Kidney Disease - Therapeutics under Development by Companies 11
Polycystic Kidney Disease - Therapeutics under Investigation by Universities/Institutes 12
Polycystic Kidney Disease - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Polycystic Kidney Disease - Products under Development by Companies 16
Polycystic Kidney Disease - Products under Investigation by Universities/Institutes 17
Polycystic Kidney Disease - Companies Involved in Therapeutics Development 18
DiscoveryBiomed, Inc. 18
Endocyte, Inc. 19
IC-MedTech, Inc. 20
Ipsen S.A. 21
Kadmon Corporation, LLC 22
Metabolic Solutions Development Company, LLC 23
Otsuka Holdings Co., Ltd. 24
Synta Pharmaceuticals Corp. 25
Polycystic Kidney Disease - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(ascorbic acid + menadione) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
DBM-43H11 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drugs for Polycystic Kidney Disease - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
EC-0371 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
JP-153 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
lanreotide acetate - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MSDC-0160 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MSDC-0602 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule to Inhibit Xanthine Oxidase for Polycystic Kidney Disease - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules to Target CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
STA-2842 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
tesevatinib tosylate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
tolvaptan - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Polycystic Kidney Disease - Recent Pipeline Updates 59
Polycystic Kidney Disease - Dormant Projects 68
Polycystic Kidney Disease - Discontinued Products 69
Polycystic Kidney Disease - Product Development Milestones 70
Featured News & Press Releases 70
May 28, 2015: Otsuka's JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease 70
Mar 18, 2015: Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease 71
Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease 71
Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease 72
Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide 73
Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease 74
Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease 75
May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease 75
Mar 24, 2014: Otsuka Pharmaceutical's Samsca Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease 75
Dec 27, 2013: European Medicines Agency Accepts Otsuka's Marketing Authorisation Application for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease 76
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 78
Disclaimer 79

List of Tables

Number of Products under Development for Polycystic Kidney Disease, H1 2015 9
Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed, Inc., H1 2015 18
Polycystic Kidney Disease - Pipeline by Endocyte, Inc., H1 2015 19
Polycystic Kidney Disease - Pipeline by IC-MedTech, Inc., H1 2015 20
Polycystic Kidney Disease - Pipeline by Ipsen S.A., H1 2015 21
Polycystic Kidney Disease - Pipeline by Kadmon Corporation, LLC, H1 2015 22
Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company, LLC, H1 2015 23
Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 24
Polycystic Kidney Disease - Pipeline by Synta Pharmaceuticals Corp., H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Assessment by Combination Products, H1 2015 27
Number of Products by Stage and Target, H1 2015 29
Number of Products by Stage and Mechanism of Action, H1 2015 31
Number of Products by Stage and Route of Administration, H1 2015 33
Number of Products by Stage and Molecule Type, H1 2015 35
Polycystic Kidney Disease Therapeutics - Recent Pipeline Updates, H1 2015 59
Polycystic Kidney Disease - Dormant Projects, H1 2015 68
Polycystic Kidney Disease - Discontinued Products, H1 2015 69